Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.
about
Human cytomegalovirus and transplantation: drug development and regulatory issuesGenomic and functional characteristics of human cytomegalovirus revealed by next-generation sequencingProgress in the development of new therapies for herpesvirus infectionsDistribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymeraseIn vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action.Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients.Cytomegalovirus infection in liver transplant recipients: updates on clinical managementThe development of new therapies for human herpesvirus 6.Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies.β-l-1-[5-(E-2-bromovinyl)-2-(hydroxymethyl)-1,3-(dioxolan-4-yl)] uracil (l-BHDU) prevents varicella-zoster virus replication in a SCID-Hu mouse model and does not interfere with 5-fluorouracil catabolism.Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.Human herpesvirus vaccines and future directions.Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.Potency and Stereoselectivity of Cyclopropavir Triphosphate Action on Human Cytomegalovirus DNA Polymerase.Resistance of human cytomegalovirus to cyclopropavir maps to a base pair deletion in the open reading frame of UL97.
P2860
Q26700020-10F348A7-82EE-4101-AA26-CE014150EF9CQ28541706-62A5ADCB-81CE-4B5A-B893-A2E5F3FCCE80Q35590695-DD1E7437-FB50-4861-A320-074C3AAD7856Q37523020-128D4E0D-4272-4DAF-9957-C8302DB05935Q37544751-6E8518C7-2FE2-433D-BAA3-4532269F325BQ38067694-457CDFDE-8AF0-4F43-A8D4-2C6FDD6644F3Q38242802-D1EBEFB2-7704-4971-B436-300BAAF4C9C3Q38280949-AFCE25BE-1136-4457-9BD1-CD8F45318AC4Q38694084-01B21904-7367-48CC-970E-6A9351400355Q38972819-B28AC00D-7064-467C-AC08-A909C7702C02Q39155340-BC7767C1-B069-4CA0-ADD9-6AAFF74FC4AAQ39476453-D1618D3F-CDB9-48B4-9048-6B2DBD09FC9CQ40325104-BC0DE5DA-D840-46C2-86F9-115B941943EEQ40771642-ABE0E471-C6F6-417D-9355-BA03D6EE3C15Q42286758-00ADC518-5C0F-4BC2-ADCD-37DB983ED0ED
P2860
Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.
@ast
Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.
@en
type
label
Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.
@ast
Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.
@en
prefLabel
Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.
@ast
Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.
@en
P2093
P2860
P356
P1476
Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase
@en
P2093
Caroll B Hartline
David M Engelthaler
Earl R Kern
Elizabeth M Driebe
Emma A Harden
James M Schupp
Paul S Keim
Scott H James
Terry L Bowlin
P2860
P304
P356
10.1128/AAC.00571-11
P407
P577
2011-07-25T00:00:00Z